306 related articles for article (PubMed ID: 15561844)
21. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
Di Vincenzo P; Rusconi S; Adorni F; Vitiello P; Maggiolo F; Francisci D; Di Biagio A; Monno L; Antinori A; Boeri E; Punzi G; Perno CF; Callegaro A; Bruzzone B; Zazzi M;
HIV Med; 2010 Sep; 11(8):530-4. PubMed ID: 20236364
[TBL] [Abstract][Full Text] [Related]
22. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Zhang Z; Xu W; Koh YH; Shim JH; Girardet JL; Yeh LT; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2007 Feb; 51(2):429-37. PubMed ID: 17116677
[TBL] [Abstract][Full Text] [Related]
23. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
[TBL] [Abstract][Full Text] [Related]
24. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
25. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
[TBL] [Abstract][Full Text] [Related]
26. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
27. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
[TBL] [Abstract][Full Text] [Related]
28. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
[TBL] [Abstract][Full Text] [Related]
29. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
30. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Corbau R; Mori J; Phillips C; Fishburn L; Martin A; Mowbray C; Panton W; Smith-Burchnell C; Thornberry A; Ringrose H; Knöchel T; Irving S; Westby M; Wood A; Perros M
Antimicrob Agents Chemother; 2010 Oct; 54(10):4451-63. PubMed ID: 20660667
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
32. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
[TBL] [Abstract][Full Text] [Related]
33. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
34. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Wildum S; Paulsen D; Thede K; Ruebsamen-Schaeff H; Zimmermann H
Antimicrob Agents Chemother; 2013 Nov; 57(11):5320-9. PubMed ID: 23959304
[TBL] [Abstract][Full Text] [Related]
36. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
Parkin NT; Gupta S; Chappey C; Petropoulos CJ
Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
[TBL] [Abstract][Full Text] [Related]
37. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
38. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
39. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
40. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP; McNicholl IR
Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
